[Expert consensus on the clinical application of oral small-molecule antiviral drugs against COVID-19].

Society of Bacterial Infection and Resistance of Chinese Medical Association; National Clinical Research Center for Respiratory Disease; National Center for Respiratory Medicine

Publisher: Zhonghua yi xue hui Country of Publication: China NLM ID: 7511141 Publication Model: Print Cited Medium: Print ISSN: 0376-2491 (Print) Linking ISSN: 03762491 NLM ISO Abbreviation: Zhonghua Yi Xue Za Zhi Subsets: MEDLINE

Publication: Beijing : Zhonghua yi xue hui
Original Publication: Beijing : Zhonghua yi xue hui.

Antiviral Agents*/therapeutic use ; COVID-19* ; SARS-CoV-2* ; Pandemics*; Humans ; Pneumonia, Viral/drug therapy ; COVID-19 Drug Treatment ; Coronavirus Infections/drug therapy ; Consensus ; Betacoronavirus ; Administration, Oral ; China ; Pregnancy

Although COVID-19 no longer constitutes a "public health emergency of international concern", which still has being spreading around the world at a low level. Small molecule drugs are the main antiviral treatment for novel coronavirus recommended in China. Although a variety of small-molecule antiviral drugs against COVID-19 have been listed in China, there is no specific drug recommendation for special populations. Society of Bacterial Infection and Resistance of Chinese Medical Association, together with the National Clinical Research Center for Respiratory Disease, and the National Center for Respiratory Medicine, organized domestic experts in various fields such as respiratory, virology, infection, critical care, emergency medicine and pharmacy to release Expert Consensus on the Clinical Application of Oral Small-Molecule Antiviral Drugs against COVID-19. The main content of this consensus includes the introduction of seven small-molecule antiviral drugs against COVID-19, focusing on the drug recommendations for 14 special groups such as the elderly, patients with complicated chronic diseases, tumor patients, pregnant women, and children, and providing suggestions for clinicians to standardize drug use.

EKPG21-06 Emergency Key Program of Guangzhou Laboratory; 0022/2021/A1 the Macao Science and Technology Development Fund; 2021TQ060189 the Young Top Talent of Science and Technology Innovation Department of Guangdong Province; ZYYCXTU-D-202201 National Administration of Traditional Chinese Medicine's Interdisciplinary Innovation Team Project

Local Abstract: [Publisher, Chinese] 新型冠状病毒（新冠病毒）感染虽已不再构成“国际关注的突发公共卫生事件”，但仍在全球范围内处于低水平流行。小分子口服药物是我国目前推荐的针对新冠病毒感染的主要抗病毒治疗方案。虽然国内已上市多种抗新冠病毒小分子药物，但目前尚无针对特殊人群的具体用药推荐。中华医学会细菌感染与耐药防治分会联合国家呼吸医学中心、国家呼吸系统疾病临床医学研究中心组织国内呼吸、病毒学、感染、重症、急诊、药学等各领域专家制订了本共识。本共识的主要内容包括7种抗新冠病毒小分子药物介绍，重点阐述了老年人群、合并慢性疾病人群、肿瘤患者、孕妇、儿童等14种特殊人群用药推荐，为临床医师规范用药提供建议。.

0 (Antiviral Agents)

Date Created: 20240523 Date Completed: 20240523 Latest Revision: 20240614

20240615

10.3760/cma.j.cn112137-20240124-00177

38782749